ArticleInternational journal of clinical and experimental pathology2014
RNA-seq reveals determinants for irinotecan sensitivity/resistance in colorectal cancer cell lines.
Article in International journal of clinical and experimental pathology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 18 citations in OpenAlex.
- Integrative In Silico and FFPE Tissue Analyses Elucidate Upregulated Genes in Colorectal Cancer Enriched for Tie2-Expressing Macrophages/Monocytes.International journal of molecular sciences · 2026Article
- Article
- Human-derived osteoblast-like cells and pericyte-like cells induce distinct metastatic phenotypes in primary breast cancer cells.Experimental biology and medicine (Maywood, N.J.) · 2021Article
- Development of Self-Associating SN-38-Conjugated Poly(ethylene oxide)-Poly(ester) Micelles for Colorectal Cancer Therapy.Pharmaceutics · 2020Article
- Role of CITED2 in stem cells and cancer.Oncology letters · 2020Review
- Review
- Next-generation sequencing: recent applications to the analysis of colorectal cancer.Journal of translational medicine · 2017Review
- Role of AXL in invasion and drug resistance of colon and breast cancer cells and its association with p53 alterations.World journal of gastroenterology · 2017Article
- Cdc20 overexpression is involved in temozolomide-resistant glioma cells with epithelial-mesenchymal transition.Cell cycle (Georgetown, Tex.) · 2017Article
- CITED2 in breast carcinoma as a potent prognostic predictor associated with proliferation, migration and chemoresistance.Cancer science · 2016Article
- Irinotecan metabolite SN38 results in germ cell loss in the testis but not in the ovary of prepubertal mice.Molecular human reproduction · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Irinotecan is a topoisomerase I inhibitor approved worldwide as a first- and second-line chemotherapy for advanced or recurrent colorectal cancer (CRC). Although irinotecan showed significant survival advantage for patients, a relatively low response rate and severe adverse effects demonstrated the urgent need for biomarkers searching to select the suitable patients who can benefit from irinotecan-based therapy and avoid the adverse effects. In present work, the irinotecan response (IC50 doses) of 20 CRC cell lines were correlated with the basal expression profiles investigated by RNA-seq to figure out genes responsible for irinotecan sensitivity/resistance. Genes negatively or positively correlated to irinotecan sensitivity were given after biocomputation, and 7 (CDC20, CTNNAL1, FZD7, CITED2, ABR, ARHGEF7, and RNMT) of them were validated in two CRC cell lines by quantitative real-time PCR, several of these 7 genes has been proposed to promote cancer cells proliferation and hence may confer CRC cells resistance to irinotecan. Our work might provide potential biomarkers and therapeutic targets for irinotecan sensitivity in CRC cells.
Indexed as
Identifiers
24966994PMC4069966W1845202093What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.